Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip?
With the stock near a 5-year low, is it worth a look?
Overview
Shares of Novo Nordisk (NYSE:NVO) dropped 9.4% today after the Danish drugmaker announced that its experimental heart drug ziltivekimab failed a critical Stage 3 clinical trial. The trial, nicknamed “Zeus,” was the first of three late-stage trials for ziltivekimab to announce results; two other trials, named “Hermes” and “Artemis,” are expected to conclude in the first half of 2027.
But is today’s drop a buying opportunity? Here’s what investors need to know.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.